公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2019 | Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer | Yun M.R; Choi H.M; Lee Y.W; Joo H.S; Park C.W; Choi J.W; Kim D.H; Kang H.N; Pyo K.-H; Shin E.J; Shim H.S; Soo R.A; CHIH-HSIN YANG ; Lee S.S; Chang H; Kim M.H; Hong M.H; Kim H.R; Cho B.C. | EMBO Molecular Medicine | 38 | 34 | |
2020 | Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations | Paik P.K.; Felip E.; Veillon R.; Sakai H.; Cortot A.B.; Garassino M.C.; Mazieres J.; Viteri S.; Senellart H.; van Meerbeeck J.; Raskin J.; Reinmuth N.; Conte P.; Kowalski D.; Cho B.C.; Patel J.D.; Horn L.; Griesinger F.; Han J.-Y.; Kim Y.-C.; Chang G.-C.; Tsai C.-L.; CHIH-HSIN YANG ; Chen Y.-M.; Smit E.F.; van der Wekken A.J.; Kato T.; Juraeva D.; Stroh C.; Bruns R.; Straub J.; Johne A.; Scheele J.; Heymach J.V.; Le X. | New England Journal of Medicine | 481 | 409 | |
2020 | Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial | Wu Y.-L.; Cheng Y.; Zhou J.; Lu S.; Zhang Y.; Zhao J.; Kim D.-W.; Soo R.A.; Kim S.-W.; Pan H.; Chen Y.-M.; Chian C.-F.; Liu X.; Tan D.S.W.; Bruns R.; Straub J.; Johne A.; Scheele J.; Park K.; CHIH-HSIN YANG ; Liu Z.; Chen X.; Wang M.; Yu S.; Zhang H.; Fang J.; Li W.; Yang C.-H.; Chang G.-C.; Hsia T.-C.; Yang C.-T.; Wang C.-C.; Cho B.C.; Lee K.H.; Kim Y.-C.; An H.J.; Woo I.S.; Cho J.Y.; Shin S.W.; Lee J.-S.; Kim J.-H.; Yoo S.S.; Kato T.; Shinagawa N.; Tan S.W.D.; Ngo L.S.-M.; Ratnavelu K.; Ahmad A.R.; Liam C.K.; de Marinis F.; Tassone P.; Molla A.I.; Calles Blanco A.; Lazaro Quintela M.E.; Felip Font E.; Dingemans A.-M.; Bui L. | The Lancet Respiratory Medicine | 161 | 128 | |
2022 | Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3) | Okada M.; Kato K.; Cho B.C.; Takahashi M.; Lin C.-Y.; Chin K.; Kadowaki S.; Ahn M.-J.; Hamamoto Y.; Doki Y.; Yen C.-C.; Kubota Y.; Kim S.-B.; CHIH-HUNG HSU ; Holtved E.; Xynos I.; Matsumura Y.; Takazawa A.; Kitagawa Y. | Clinical Cancer Research | 18 | 16 |